|41.49|| -2.01 / -4.62%|
Radius Health, Inc. a biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of osteoporosis and other women's health conditions. Its principal product includes the BA058 Injection, a daily subcutaneous injection of novel synthetic peptide analog of human parathyroid hormone-related protein, which is in Phase III clinical development for the treatment of osteoporosis. The company also develops BA058 Microneedle Patch, a Phase Ib clinical development transdermal form of BA058 delivered using a microneedle technology; RAD1901, a selective estrogen receptor modulator that is in Phase II clinical development for the treatment of vasomotor symptoms in women entering menopause; and RAD140, a selective androgen receptor modulator, which is in preclinical development stage for the treatment of age-related muscle loss, frailty, and weight loss associated with cancer cachexia and osteoporosis. It has collaborations and license agreements with Nordic Bioscience Clinical Development VII A/S; 3M Drug Delivery Systems; Ipsen Pharma SAS; Eisai Co. Ltd.; Lonza Group Ltd.; and Charles River Laboratories, Inc. Radius Health was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt and John T. Potts on October 3, 2003 and is headquartered in Cambridge, MA.
|Robert E. Ward||President, Chief Executive Officer & Director|
|Brian Nicholas Harvey||CFO, Secretary, Treasurer & Senior Vice President|
|Gary Hattersley||Chief Scientific Officer|
|John Yates||Chief Medical Officer|
|Dinesh Purandare||Senior Vice President & Head-Global Oncology|